DE69718668T2 - Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend - Google Patents

Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend

Info

Publication number
DE69718668T2
DE69718668T2 DE69718668T DE69718668T DE69718668T2 DE 69718668 T2 DE69718668 T2 DE 69718668T2 DE 69718668 T DE69718668 T DE 69718668T DE 69718668 T DE69718668 T DE 69718668T DE 69718668 T2 DE69718668 T2 DE 69718668T2
Authority
DE
Germany
Prior art keywords
fatty acid
liquid composition
protease inhibitors
hiv protease
including hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69718668T
Other languages
English (en)
Other versions
DE69718668D1 (de
Inventor
John Lipari
A Al-Razzak
Soumojeet Ghosh
Rong Gao
Dilip Kaul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25034589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69718668(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69718668D1 publication Critical patent/DE69718668D1/de
Application granted granted Critical
Publication of DE69718668T2 publication Critical patent/DE69718668T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE69718668T 1996-11-21 1997-11-12 Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend Expired - Lifetime DE69718668T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75439096A 1996-11-21 1996-11-21
PCT/US1997/020794 WO1998022106A1 (en) 1996-11-21 1997-11-12 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69718668D1 DE69718668D1 (de) 2003-02-27
DE69718668T2 true DE69718668T2 (de) 2003-10-02

Family

ID=25034589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69718668T Expired - Lifetime DE69718668T2 (de) 1996-11-21 1997-11-12 Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend

Country Status (26)

Country Link
EP (2) EP0942721B1 (de)
JP (2) JP3592337B2 (de)
KR (2) KR100478075B1 (de)
CN (3) CN1250219C (de)
AR (2) AR010634A1 (de)
AT (1) ATE231393T1 (de)
AU (1) AU717546B2 (de)
BG (1) BG64411B1 (de)
BR (1) BR9714310A (de)
CA (2) CA2505430A1 (de)
CZ (1) CZ299728B6 (de)
DE (1) DE69718668T2 (de)
DK (1) DK0942721T3 (de)
ES (1) ES2191862T3 (de)
HK (1) HK1053787A1 (de)
HU (1) HU224319B1 (de)
IL (1) IL129300A (de)
NO (1) NO326927B1 (de)
NZ (1) NZ335002A (de)
PL (1) PL190185B1 (de)
PT (1) PT942721E (de)
SK (1) SK285022B6 (de)
TR (1) TR199901129T2 (de)
TW (1) TW475895B (de)
WO (1) WO1998022106A1 (de)
ZA (1) ZA9710071B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
EP0989851B1 (de) * 1997-07-29 2002-10-02 PHARMACIA & UPJOHN COMPANY Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
JP5005847B2 (ja) * 1997-07-29 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 親油性化合物用の自己乳化性処方
NZ502569A (en) * 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
EP1712231A3 (de) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Methode zur Verbesserung der Pharmakokinetik von Tipranavir
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
DE60042092D1 (de) * 1999-06-04 2009-06-04 Abbott Lab Arzneizubereitungen enthaltend mindestens einen HIV Preoteaseinhibitor
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE60019334T2 (de) * 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
ES2676151T3 (es) * 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
WO2002096395A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
BR0302424A (pt) * 2003-07-23 2005-03-29 Cristalia Prod Quimicos Farm Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US7718633B2 (en) * 2004-07-06 2010-05-18 Abbott Laboratories Prodrugs of HIV protease inhibitors
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
CN104411300A (zh) 2012-05-03 2015-03-11 希普拉有限公司 抗逆转录病毒组合物
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (de) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hemmer des hepatitis-c-virus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164839T1 (de) * 1990-11-19 1998-04-15 Monsanto Co Retrovirale proteaseinhibitoren
EP0765873B1 (de) * 1991-10-11 2002-04-17 Dupont Pharmaceuticals Company Cyclische Harnstoffe und Analoga verwendbar als retrovirale Proteasehemmer
ES2112880T3 (es) * 1991-11-08 1998-04-16 Merck & Co Inc Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0641333T3 (da) * 1992-05-20 1996-09-02 Monsanto Co Fremgangsmåde til fremstilling af mellemprodukter, som er anvendelige ved syntese af retrovirus- protease-inhibitorer
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
KR100187990B1 (ko) * 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
CN1989963B (zh) 2011-06-29
CA2271196A1 (en) 1998-05-28
NO992427D0 (no) 1999-05-20
KR20000057169A (ko) 2000-09-15
PL190185B1 (pl) 2005-11-30
ES2191862T3 (es) 2003-09-16
KR100516567B1 (ko) 2005-09-22
TW475895B (en) 2002-02-11
HUP0002932A2 (hu) 2001-01-29
AU717546B2 (en) 2000-03-30
EP0942721B1 (de) 2003-01-22
HK1053787A1 (zh) 2003-11-07
CN1250219C (zh) 2006-04-12
BG103425A (en) 2000-04-28
JP2004346077A (ja) 2004-12-09
EP0942721A1 (de) 1999-09-22
CN101103984A (zh) 2008-01-16
SK65599A3 (en) 1999-12-10
CN1989963A (zh) 2007-07-04
JP3592337B2 (ja) 2004-11-24
CA2271196C (en) 2005-06-28
CN1248914A (zh) 2000-03-29
PL336980A1 (en) 2000-07-31
CZ160299A3 (cs) 1999-08-11
HUP0002932A3 (en) 2001-03-28
JP4523799B2 (ja) 2010-08-11
DE69718668D1 (de) 2003-02-27
ZA9710071B (en) 1998-05-25
AR010634A1 (es) 2000-06-28
HU224319B1 (hu) 2005-07-28
AU5257398A (en) 1998-06-10
NO326927B1 (no) 2009-03-16
PT942721E (pt) 2003-06-30
KR100478075B1 (ko) 2005-03-23
AR048891A2 (es) 2006-06-07
KR20040004426A (ko) 2004-01-13
ATE231393T1 (de) 2003-02-15
CZ299728B6 (cs) 2008-11-05
EP1283041A1 (de) 2003-02-12
TR199901129T2 (xx) 2001-05-21
DK0942721T3 (da) 2003-05-19
IL129300A0 (en) 2000-02-17
JP2000515555A (ja) 2000-11-21
SK285022B6 (sk) 2006-04-06
WO1998022106A1 (en) 1998-05-28
NZ335002A (en) 2001-08-31
BG64411B1 (bg) 2005-01-31
NO992427L (no) 1999-07-20
IL129300A (en) 2003-07-06
CA2505430A1 (en) 1998-05-28
BR9714310A (pt) 2000-05-02

Similar Documents

Publication Publication Date Title
DE69718668D1 (de) Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
BR9712544B1 (pt) Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
HUP0200347A2 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
DK0791046T3 (da) Detergentsammensætninger, der indeholder lipase og protease
ATE236146T1 (de) Alpha-9 integrin antagonisten sowie diese enthaltende anti-inflammatorisch wirkende zusammensetzungen
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
DK1105122T3 (da) Pharmaceutical compositions containing lipase inhibitors
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
DE69707650T2 (de) Reinigungsmittel die xanthangummi und vernetzte polyacylsäure enthalten
IL128664A (en) Heterocyclic metalloprotease inhibitors and pharmaceutical compositions comprising them
BR9708793A (pt) Composições ácidas redutoras de cisalhamento espessas
EE200200286A (et) Uued aminopropüülfosfiinhapped ning nende kasutamine
DE69723395D1 (de) Aromatische ester von polyalkylphenoxyalkanolen und treibstoffzusammensetzungen, die letztere enthalten
HUP0101699A3 (en) Benzoxazinones/benzothiazinones as serine protease inhibitors and pharmaceutical compositions containing the same
DE69937679D1 (de) Wasserlösliche zusammensetzung enthaltend aktive inhaltsstoffe zur depigmentierung der haut
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
FI964342A (fi) Halogeenimetyyliamideja IL-1beta-proteaasi-inhibiittoreina
FI935780A (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
PT1214302E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase
DE69927585D1 (de) Alpha-hydroxy fettsäurenderivate und zubereitungen zur äusserlichen anwendung diese enthaltend
IL151197A0 (en) Thiazepinyl hydroxamic acid derivatives and pharmaceutical compositions containing the same
HU9802886D0 (en) Substituted heterocyclic benzocycloalkenes and their use as analgetic active ingredients
MA26540A1 (fr) Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
NO20004664L (no) FremgangsmÕte for fremstilling av HIV proteaseinhibitorer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition